bioAffinity Technologies Inc. BIAF stock is trading higher on Tuesday as the company announced plans to advance the application of its CyPath Lung test. The company is pursuing the diagnostic tool for ...
SINGAPORE, May 20, 2025 /PRNewswire/ -- In a bold step toward equitable cancer care, Gene Solutions introduces SPOT-MAS Lung, a next-generation blood-based test powered by artificial intelligence (AI) ...
Lung cancer kills more people worldwide than any other malignancy, and the reason is painfully simple: it is usually caught ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit ...
Research awards will set the stage for clinical testing of most promising tests LOS ANGELES, July 29, 2026 /PRNewswire/ -- Stand Up To Cancer® (SU2C) has awarded funding to three research teams ...
SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...
For patients with a stubborn lung infection, waiting more than a month to learn which bacterium is responsible can delay the next step in care. That is a particular problem with nontuberculous ...
Lung cancer is the leading cause of death from cancer. It kills more people in the U.S. than breast, prostate, and colon cancer combined. When lung adenocarcinoma, the most common primary lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results